Find a Physician How to Contribute Affiliated Hospitals Clinical Trials

Search Clinical Trials

Search term was Gastrointestinal: Liver
# Protocol Status Title Purpose Study Type
1 DRUG BAY-1187982-16897 OPEN An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate Bay 1187982 in Subjects with Advanced Solid Tumors Known to Express FGFR2 The purpose of this study is to evaluate the safety, tolerability (the effect of the study drug on the body), of BAY 1187982 when given as a single agent in patients with advance or refractory (has not responded to other treatment) solid tumors. Therapeutic
2 DRUG C34001 OPEN An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe. Therapeutic
3 DRUG CBGJ398XUS04 OPEN Modular phase II study to link targeted therapy to patients with pathway activated tumors:Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations Researchers want to know if BGJ398 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a FGFR regulated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen. Therapeutic
4 DRUG CLDK378AUS23 OPEN Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1 The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway. Therapeutic
5 DRUG H9H-MC-JBAK OPEN Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma The purpose of this study is to determine what dose of LY2157299 can safely be given to patients with liver cancer, whether LY2157299 can help patients with liver cancer and to evaluate the biologic effects of LY2157299. Therapeutic
6 DRUG INCB 54329-101 PENDING Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies The purpose of this study is to find out how safe and tolerable the study drug INCB054329 is in patients with advanced types of cancer (including solid tumors and blood cancers). This study will mainly answer the following: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that enters and leaves the body over time and the effects it has on the body; 3) preliminary evidence of whether or not the drug has any anti-cancer effects. Therapeutic
7 DRUG TS-103 OPEN A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC) The purpose of this research study is to see if adding TheraSphere treatment before the current standard of care therapy Nexavar (sorafenib) lengthens survival time and is safe and better than the current treatment alone. Therapeutic
8 DRUG TS-104 OPEN A prospective randomized clinical trial on 90Yttrium trans-arterial radio-Embolization (TheraSphere®) vs. Sorafenib for the treatment of advanced Hepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT) The purpose of this study is to see if TheraSphere (medical device that delivers therapy directly to the tumor) lengthens survival time and is safer than sorafenib (current standard treatment)for treating hepatocellular carcinoma (cancer in the liver)in participants with portal vein thrombosis (a clot in the major vein of the liver). Therapeutic
9 NCI 12CC11 OPEN Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial The main purpose of this research study is to compare 12 versus 24 weeks of varenicline, also known as Chantix® [12 week] for smoking cessation. Supportive Care
10 NU 10C03 OPEN Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is. Therapeutic
11 NU 12C06 OPEN A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer. Therapeutic
12 NU 12CC12 OPEN A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety To test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population. Therapeutic
13 NU 14CC08 OPEN REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer. Supportive Care
14 NU PRE0204 OPEN A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma The main purpose of this study is to find out what effects (good and/or bad) the drug combination of Nab-Paclitaxel and Gemcitabine has on advanced or metastatic cholangiocarcinoma. Therapeutic
15 RTOG 0631 OPEN Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects. Therapeutic
16 RTOG 1112 OPEN Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib In Hepatocellular Carcinoma The purpose of this study is to compare the effects of sorafenib alone (standard of care) with stereotactic body radiation therapy (SBRT) followed by sorafenib. Therapeutic

Clinical trial availability changes frequently. Please check this site for new or updated trials that pertain to you. If you have questions about current or future trials, contact the Cancer Center at 866-LURIE-CC (866-587-4322) or

About Us | Job Opportunities | Northwestern University | Maps & Directions | Contact Us
© Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Clinical Cancer Center: 866.LURIE.CC || Chicago Administrative Office: 312.908.5250.
Contact us with questions at:
National Comprhensive Cancer Network National Cancer Institute You Tube Facebook